Donald A. Bergstrom - Apr 28, 2022 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
President, R&D
Signature
/s/ Brian Adams, as attorney-in-fact
Stock symbol
RLAY
Transactions as of
Apr 28, 2022
Transactions value $
-$312,807
Form type
4
Date filed
5/2/2022, 08:24 PM
Previous filing
Apr 5, 2022
Next filing
Jun 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Sale -$46.3K -1.81K -1.92% $25.57 92.5K Apr 28, 2022 Direct F1, F2
transaction RLAY Common Stock Options Exercise $53.6K +13K +14.06% $4.12 105K May 2, 2022 Direct F2, F3
transaction RLAY Common Stock Sale -$320K -13K -12.32% $24.62 92.5K May 2, 2022 Direct F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Options Exercise $0 -13K -6.52% $0.00 186K May 2, 2022 Common Stock 13K $4.12 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 4,059 shares of restricted stock units ("RSUs") on April 27, 2022. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
F2 Includes 87,141 shares underlying RSUs.
F3 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022.
F4 This transaction was executed in multiple trades at prices ranging from $23.09 to $25.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5 Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.